Burning Rock Biotech (NASDAQ:BNR) Raised to “Buy” at Wall Street Zen

Burning Rock Biotech (NASDAQ:BNR) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Burning Rock Biotech Trading Down 3.9%

Shares of Burning Rock Biotech stock opened at $32.01 on Friday. Burning Rock Biotech has a twelve month low of $2.18 and a twelve month high of $34.79. The company has a quick ratio of 2.91, a current ratio of 3.14 and a debt-to-equity ratio of 0.03. The business has a 50-day moving average price of $19.64 and a 200-day moving average price of $12.08. The firm has a market cap of $344.43 million, a price-to-earnings ratio of -19.28 and a beta of 1.25.

Institutional Trading of Burning Rock Biotech

Institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. purchased a new position in Burning Rock Biotech in the 3rd quarter worth about $26,000. Prospera Financial Services Inc bought a new position in Burning Rock Biotech in the 3rd quarter worth about $214,000. Finally, Crcm LP increased its position in shares of Burning Rock Biotech by 13.8% during the third quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after acquiring an additional 26,809 shares during the period. 30.03% of the stock is currently owned by institutional investors.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.